*Review key diagnostic criteria for PBC - emphasizing newer roles for PBC-specific Anti-Nuclear Antibodies (ANAS) gp210 and sp100
*Discuss the role of biopsy and alternative non-invasive ways to assess and monitor the fibrosis stage
*Define the criteria for diagnosis of an Overlap Syndrome with Autoimmune Hepatitis
*Review standard of care Therapies and the Phase 3 Clinical Trial results of elfibranor and seladelpar, the 2 PPARS being considered for FDA approval as second-line therapies